The Munich-based buyout firm has just closed the largest acquisition in its history, yet the share price response has been muted at best. That disconnect — between a flurry of transformative deals and a stock trading roughly a quarter below its January peak — frames the central question for investors as Mutares enters the second half of its fiscal year.
At the heart of the matter is a gap between operational momentum and shareholder returns. The company’s first-half figures, released on August 18, showed group revenue climbing to EUR 3.4 billion, a 9 percent improvement year on year, while adjusted EBITDA swung from minus EUR 89 million to plus EUR 67 million. But the adjusted net result tells a less flattering story: it collapsed to EUR 6 million from EUR 70 million in the prior-year period. Holding-level revenue from consulting and management fees also slipped to EUR 49 million.
That divergence raises a pointed question: does the operational recovery actually reach shareholders, or do integration costs, financing charges and dilution from the spring capital increase eat up the progress before it hits the bottom line?
A Deal Pipeline Running Hot
The scale of recent activity is hard to overstate. In early August, Mutares completed the acquisition of SABIC’s engineering thermoplastics business in the Americas and Europe — a transaction valued at USD 450 million. The former division, now operating as NexPoint Materials, brings roughly EUR 2.0 billion in annual revenue, about 2,800 employees and eight production sites across two continents. It also anchors a new “Chemicals & Materials” segment, shifting the group’s portfolio more decisively toward chemistry and material science.
Shortly after, the company closed the purchase of Magna International’s car-top systems business, a division that traces its roots to a former joint venture involving Mercedes and Porsche. A deal to acquire Free2move from Stellantis remains pending, with completion expected around year-end.
The consolidation of these newly acquired businesses — not organic growth — is what’s driving the top-line expansion. That’s consistent with Mutares’ traditional model of buying, restructuring and eventually divesting corporate divisions, but the sheer pace of transactions this year has intensified scrutiny on how quickly newly integrated assets can be converted into profitable growth.
Balance Sheet Discipline Offers Some Comfort
For investors focused on leverage, the company’s confirmation that it remains in compliance with all bond covenants was a meaningful signal — particularly given the simultaneous financing of multiple sizeable acquisitions. The fact that Mutares has maintained its debt conditions despite the scale of recent deals suggests the financing structure has held up so far.
Still, the profitability math remains thin. Adjusted EBITDA of EUR 67 million against a revenue base of EUR 3.4 billion underscores how narrow group margins are at this stage. Revenue growth alone, the market seems to be saying, says little about the sustainability of margins.
Should investors sell immediately? Or is it worth buying Mutares?
The Bear Case: Integration Risk and Dilution
The risks are not hard to identify. Adding EUR 2.0 billion in revenue through NexPoint Materials means absorbing significant operational complexity across eight sites in different regulatory and economic environments. If the adjusted net result stays at its current low level — or deteriorates further — the capital increase approved in April, which raised gross proceeds of up to EUR 105 million and could dilute existing shareholders by up to 20 percent, would look increasingly burdensome in hindsight.
The Free2move transaction, still pending, adds another layer of uncertainty. A setback or delay beyond year-end would likely weigh on confidence in the group’s acquisition and exit strategy.
The share price reflects this caution. Trading at around EUR 26.00, the stock sits roughly 26 percent below its 52-week high of EUR 35.15, reached in mid-January. Since the start of the year, it has lost about 14 percent. The market, it appears, is not rewarding the acquisition spree with a valuation premium — it’s waiting to see whether the operational turnaround translates into sustainable net earnings.
What Would Change the Narrative
The bull case rests on execution. If NexPoint Materials integrates smoothly, the additional revenue should secure the upper end of the 2026 guidance. The company has reaffirmed its full-year outlook of EUR 7.9 billion to EUR 9.1 billion in group revenue and a holding-level net profit of EUR 165 million to EUR 200 million.
Sphene Capital reiterated its buy rating on August 6 with a price target of EUR 49.30 — a marginal, valuation-driven reduction from EUR 49.40, attributed to higher discount rates rather than operational weakness. Should the second half confirm the EBITDA turnaround and push holding-level net income toward the upper guidance range, the gap to that target would narrow considerably.
The bear case, by contrast, hinges on integration speed and capital structure. A return to negative adjusted net income or a Free2move delay beyond year-end would likely reinforce the skepticism already priced into the stock.
The next concrete checkpoint comes in November: on November 19, Mutares hosts an investor day in London, where management is expected to offer deeper insight into integration progress and medium-term strategy. Until then, the market’s verdict on whether scale can become earnings remains very much in the balance.
Ad
Mutares Stock: Buy or Sell?! New Mutares Analysis from August 28 delivers the answer:
The latest Mutares figures speak for themselves: Urgent action needed for Mutares investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 28.
Mutares: Buy or sell? Read more here...
